RAC
RACURA ONCOLOGY ORDINARYRacura Oncology Ltd operates as a Phase 3 clinical biopharmaceutical company for cancer care. Its lead asset is RCDS1 (E,E-bisantrene), a small molecule anticancer agent that primarily functions through G4-DNA & RNA binding to potent inhibition of the cancer growth regulator MYC. The company is advancing a proprietary formulation of RCDS1 (RC220) to address the unmet needs of patients across various oncology indications with Phase 3 clinical programs in acute myeloid leukaemia, Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin. It has collaborations with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. The company was formerly known as Race Oncology Ltd and changed its name to Racura Oncology Ltd in December 2025. Racura Oncology Ltd was incorporated in 2011 and is headquartered in Sydney, Australia.
RAC
RAC
RACURA ONCOLOGY ORDINARY
Racura Oncology Ltd operates as a Phase 3 clinical biopharmaceutical company for cancer care. Its lead asset is RCDS1 (E,E-bisantrene), a small molecule anticancer agent that primarily functions through G4-DNA & RNA binding to potent inhibition of the cancer growth regulator MYC.
Fundamentals
Historical Data53 days
| Date | Short % | Gross Short |
|---|---|---|
| 16 July | — | — |
| 15 July | — | — |
| 14 July | — | — |
| 13 July | 0.01% | — |
| 10 July | 0.01% | — |
| 9 July | 0.01% | — |
| 8 July | 0.01% | — |
| 7 July | 0.01% | — |
| 6 July | 0.01% | — |
| 3 July | 0.01% | — |
| 2 July | 0.01% | — |
| 1 July | 0.01% | — |
Racura Oncology (RAC) Short Interest Summary
Racura Oncology (RAC) currently has 0.01% of its shares sold short (19 thousand shares, worth approximately $43K), based on ASIC short position data reported on 13 July 2026 (T+4 reporting lag). That makes RAC the #601 most shorted stock on the ASX most shorted list. Short interest in RAC is up 0.00% over the past week and up 0.01% over the past month. RAC is part of the Health Care sector on the ASX.
Recent RAC Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 13 July 2026 | 0.01% | 0.0M | $2.19 |
| 10 July 2026 | 0.01% | 0.0M | $2.19 |
| 9 July 2026 | 0.01% | 0.0M | $2.14 |
| 8 July 2026 | 0.01% | 0.0M | $2.12 |
| 7 July 2026 | 0.01% | 0.0M | $2.20 |
| 6 July 2026 | 0.01% | 0.0M | $2.31 |
| 3 July 2026 | 0.01% | 0.0M | $2.29 |
| 2 July 2026 | 0.01% | 0.0M | $2.28 |
| 1 July 2026 | 0.01% | 0.0M | $2.20 |
| 30 June 2026 | 0.01% | 0.0M | $2.22 |
RAC Short Selling — Frequently Asked Questions
What is Racura Oncology (RAC)'s current short interest?
Racura Oncology (RAC) currently has a short interest of 0.01% of total shares outstanding. This means 0.01% of RAC's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is RAC heavily shorted on the ASX?
RAC has a relatively low short interest of 0.01%. Short interest below 5% generally suggests limited bearish sentiment from short sellers.
What does short interest mean for RAC investors?
Short interest in RAC shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 0.01%, RAC's short interest is at a low level. See our short squeeze candidates and days to cover analysis for more context.
Where does this RAC short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for RAC.